GenVec, Inc.’s (GNVC) TNFerade™ Gets FDA Fast Track Designation for Pancreatic Cancer Treatment
Read the full article: http://Blog.QualityStocks.net/?p=13789
GenVec, Inc. reported today that the U.S. Food and Drug Administration (FDA) has approved GenVec’s TNFerade™ for Fast Track development in the treatment of locally advanced pancreatic cancer. TNFerade™ is designed to stimulate the production of immune system proteins with anti-cancer properties that are injected into tumors. GenVec is developing TNFerade™ for use in combination with other tools such as radiation and chemotherapy for the treatment of various cancers
- Login or register to post comments
- Email this page
Related Articles
- Dyax Corp. (DYAX) Announces Completion of Biologics License Application with FDA; Moves Forward with Treatment for Life-Threaten
- China Pharma Holdings Inc. (CPHI.OB) Posts Positive Q3 Results Across the Board
- CardioVascular Biotherapeutics Inc. (CVBT.OB) Finds Significant Private Funding for Topical Diabetic Wound Care Rollout
- Dyax Corp. (DYAX) Reports Statistically Significant Results in Trials to Fight Hereditary Angioedema
- BioScrip (BIOS) Quarterly Revenue and Net Income Soars